The journal of nutrition, health & aging

, Volume 20, Issue 3, pp 280–287 | Cite as

Serum cholesterol levels within the high normal range are associated with better cognitive performance among Chinese elderly

  • Y.-B. Lv
  • Z. X. Yin
  • C.-L. Chei
  • M. S. Brasher
  • J. Zhang
  • V. B. Kraus
  • F. Qian
  • Xiaoming ShiEmail author
  • D. B. Matchar
  • Y. Zeng



The association between cognitive function and cholesterol levels is poorly understood and inconsistent results exist among the elderly. The purpose of this study is to investigate the association of cholesterol level with cognitive performance among Chinese elderly.


A cross-sectional study was implemented in 2012 and data were analyzed using generalized additive models, linear regression models and logistic regression models.


Community-based setting in eight longevity areas in China.


A total of 2000 elderly aged 65 years and over (mean 85.8±12.0 years) participated in this study.


Total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) concentration were determined and cognitive impairment was defined as Mini-Mental State Examination (MMSE) score≤23.


There was a significant positive linear association between TC, TG, LDL-C, HDL-C and MMSE score in linear regression models. Each 1 mmol/L increase in TC, TG, LDL-C and HDL-C corresponded to a decreased risk of cognitive impairment in logistic regression models. Compared with the lowest tertile, the highest tertile of TC, LDL-C and HDL-C had a lower risk of cognitive impairment. The adjusted odds ratios and 95% CI were 0.73(0.62–0.84) for TC, 0.81(0.70–0.94) for LDL-C and 0.81(0.70–0.94) for HDL-C. There was no gender difference in the protective effects of high TC and LDL-C levels on cognitive impairment. However, for high HDL-C levels the effect was only observed in women. High TC, LDL-C and HDL-C levels were associated with lower risk of cognitive impairment in the oldest old (aged 80 and older), but not in the younger elderly (aged 65 to 79 years).


These findings suggest that cholesterol levels within the high normal range are associated with better cognitive performance in Chinese elderly, specifically in the oldest old. With further validation, low cholesterol may serve a clinical indicator of risk for cognitive impairment in the elderly.


Cholesterol Chronic Kidney Disease Cognitive Impairment Mild Cognitive Impairment High Density Lipoprotein Cholesterol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jia J, Zhou A, Wei C, et al. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. Alzheimers Dement 2014; 10:439–447.CrossRefPubMedGoogle Scholar
  2. 2.
    Jia J, Wang F, Wei C, et al. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement 2014;10: 1–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Muldoon MF, Flory JD, Ryan CM. Serum cholesterol, the brain, and cognitive functioning. Neuropsychology of Cardiovascular Disease. Mahwah, NJ; 2001:37–59.Google Scholar
  4. 4.
    Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009;66:343–348PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Rantanen KK, Strandberg AY, Pitkälä K, et al. Cholesterol in midlife increases the risk of Alzheimer’s disease during an up to 43-year follow-up. Eur Geriatr Med, 2014.Google Scholar
  6. 6.
    Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol-Chicago 2002;59: 378–384.CrossRefPubMedGoogle Scholar
  7. 7.
    Feng L, Chong MS, Lim WS, et al. Tea for Alzheimer Prevention. J Prev Alz Dis 2015;2:136–141.Google Scholar
  8. 8.
    Yasuno F, Tanimukai S, Sasaki M, et al. Association between cognitive function and plasma lipids of the elderly after controlling for apolipoprotein E genotype. Am J Geriat Psychiat 2012; 20: 574–583.CrossRefGoogle Scholar
  9. 9.
    Reitz C, Luchsinger J, Tang MX, et al. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 2005; 64:1378–1383.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Tukiainen TP, Jylänki VP, Mäkinen O, et al. Mild cognitive impairment associates with concurrent decreases in serum cholesterol and cholesterol-related lipoprotein subclasses. J Nutr Health Aging 2012; 16: 631–635CrossRefPubMedGoogle Scholar
  11. 11.
    Stewart R, White LR, Xue QL, et al. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2007;64:103–107.CrossRefPubMedGoogle Scholar
  12. 12.
    Yin ZX, Shi XM, Kraus VB, et al. High normal plasma triglycerides are associated with preserved cognitive function in Chinese oldest-old. Age Ageing 2012; 41:600–606.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Kuusisto J, Koivisto K, Mykkänen L, et al. Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997, 315(7115): 1045–1049.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Piguet O, Grayson D A, Creasey H, et al. Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons Study. Neuroepidemiology 2003; 22: 165–171.CrossRefPubMedGoogle Scholar
  15. 15.
    Elias P K, Elias M F, D’Agostino R B, et al. Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosomatic medicine 2005; 67: 24–30.CrossRefPubMedGoogle Scholar
  16. 16.
    van Vliet P. Cholesterol and late-life cognitive decline. Journal of Alzheimer’s Disease 2012; 30: S147–S162.PubMedGoogle Scholar
  17. 17.
    Yi Zeng. Towards deeper research and better policy for healthy aging–using the unique data of Chinese Longitudinal Healthy Longevity Survey. China Economic J 2012; 5:131–149.CrossRefGoogle Scholar
  18. 18.
    Yin ZX, Shi XM, Kraus VB, et al. Gender-dependent association of body mass index and waist circumference with disability in the Chinese oldest old. Obesity, 2014. 22:1918–1925.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.PubMedGoogle Scholar
  20. 20.
    Folstein MF, Folstein SE, McHugh PR, et al. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975;12: 189–198CrossRefPubMedGoogle Scholar
  21. 21.
    Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992;40: 922–935.CrossRefPubMedGoogle Scholar
  22. 22.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(S1): S1–266.Google Scholar
  23. 23.
    Chinese eGFR Investigation Collaboration. Modification and evaluation of MDRD estimating equation for Chinese patients with chronic kidney disease. Chinese Journal of Nephrology 2006; 22:589–595.Google Scholar
  24. 24.
    Fagan AM, Younkin LH, Morris JC, et al. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000; 48:201–210.CrossRefPubMedGoogle Scholar
  25. 25.
    Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer’s disease? J Neurosci Res 2003; 72:141–146.CrossRefPubMedGoogle Scholar
  26. 26.
    Stuart SA, Robertson JD, Marrion NV, et al. Chronic Pravastatin but Not Atorvastatin Treatment Impairs Cognitive Function in Two Rodent Models of Learning and Memory. PLoS One 2013;8:e75467.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Wagstaff LR, Mitton MW, Arvik B ML, et al. Statin Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature. Pharmacotherapy 2003; 23: 871–880.CrossRefPubMedGoogle Scholar
  28. 28.
    FDA. Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. 2012.Google Scholar
  29. 29.
    Zhang Y, Protogerou AD, Iaria P, et al. Prognosis in the hospitalized very elderly: The PROTEGER study. Int J Cardiol 2013; 168:2714–2719.CrossRefPubMedGoogle Scholar
  30. 30.
    Schupf N, Costa R, Luchsinger J, et al. Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005; 53:219–226.CrossRefPubMedGoogle Scholar
  31. 31.
    Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000;30:141–145.CrossRefPubMedGoogle Scholar
  32. 32.
    Hu P, Seeman TE, Harris TB, et al. Does inflammation or undernutrition explain the low cholesterol–mortality association in high-functioning older persons? MacArthur Studies of Successful Aging. J Am Geriatr Soc 2003;51:80–84.CrossRefPubMedGoogle Scholar
  33. 33.
    La Rue A, Koehler K M, Wayne S J, et al. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. Am J Clin Nutr 1997; 65: 20–29.PubMedGoogle Scholar
  34. 34.
    Otsuka R, Kato Y, Nishita Y, et al. Cereal intake increases and dairy products decrease risk of cognitive decline among elderly female Japanese. J Prev Alz Dis. 2014;1(3):160–167.Google Scholar
  35. 35.
    Subhan F, Khan I, Arif R, et al. Serum lipid profile as an indicator of the severity of liver damage in cirrhotic patient. Rawal Medical Journal, 2012, 37: 387–389.Google Scholar
  36. 36.
    Fan QW, Yu W, Gong JS, et al. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem 2002; 80:178–190.CrossRefPubMedGoogle Scholar
  37. 37.
    Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. Faseb J 2001;15:1858–1860.PubMedGoogle Scholar
  38. 38.
    Michikawa M, Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem 1999; 72:2278–2285.CrossRefPubMedGoogle Scholar
  39. 39.
    D.H. Mauch, K. Nagler, S. Schumacher, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001;294: 1354–1357.CrossRefPubMedGoogle Scholar
  40. 40.
    Oliver MF. Serum cholesterol–the knave of hearts and the joker. Lancet 1981;2:1090–1095.CrossRefPubMedGoogle Scholar
  41. 41.
    Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. Faseb J 2001;15:1858–1860.PubMedGoogle Scholar
  42. 42.
    Traber MG, Kayden HJ. Vitamin E is delivered to cells via the high affinity receptor for low-density lipoprotein. Am J Clin Nutr, 1984, 40: 747–751.PubMedGoogle Scholar
  43. 43.
    Zlokovic B V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57: 178–201.CrossRefPubMedGoogle Scholar
  44. 44.
    Netea MG, Demacker PN, Kullberg BJ, et al. Low density lipoprotein receptor-deficient mice are protected against lethal endtoxemia and severe Gram-negative infections. J Clin Invest 1996; 97:1366–1372.PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. JAMA 1993; 94: 515–519.CrossRefGoogle Scholar
  46. 46.
    Derecki NC, Quinnies KM, Kipnis J. Alternatively activated myeloid (M2) cells enhance cognitive function in immune compromised mice. Brain Behav Immun. 2011; 25:379–385.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Saxena, R, Amitabha C. Membrane cholesterol stabilizes the human serotonin receptor. Biochimic Biophysica Acta (BBA)-Biomembranes 2012; 1818: 2936–2942.CrossRefGoogle Scholar
  48. 48.
    Ramirez MJ, Lai MKP, Tordera RM et al. Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status. Drugs 2014; 74: 729–736.CrossRefPubMedGoogle Scholar
  49. 49.
    Huber, LA, Xu QB, Jurgens G, et al. Correlation of lymphocyte lipid composition membrane micro viscosity and mitogen response in the aged. Eur J Immunol 1991; 21:2761–2765.CrossRefPubMedGoogle Scholar
  50. 50.
    Joseph JA. Cholesterol: a two-edged sword in brain aging. Free Radical Bio Med 1997; 22: 455–462.CrossRefGoogle Scholar
  51. 51.
    Vatassery GT, Smith WE, Quach HT, et al. In vitro oxidation of vitamin E, vitamin C, thiols and cholesterol in rat brain mitochondria incubated with free radicals. Neurochem Int 1995;26:527–535.CrossRefPubMedGoogle Scholar
  52. 52.
    Knopp RH, Paramsothy P, Retzlaff BM, et al. Gender differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Atheroscler Rep 2005;7:472–479.CrossRefPubMedGoogle Scholar
  53. 53.
    Casiglia E, Tikhonoff V, Caffi S, et al. Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men. J Hyperten 2008; 26:1983–1992.CrossRefGoogle Scholar
  54. 54.
    Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14786 middle-aged men and women in Finland. Circulation 1999; 99:1165–1172.CrossRefPubMedGoogle Scholar
  55. 55.
    Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328:313–318.CrossRefPubMedGoogle Scholar
  56. 56.
    Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272:1335–1340.CrossRefPubMedGoogle Scholar

Copyright information

© Serdi and Springer-Verlag France 2016

Authors and Affiliations

  • Y.-B. Lv
    • 1
  • Z. X. Yin
    • 1
  • C.-L. Chei
    • 2
  • M. S. Brasher
    • 3
  • J. Zhang
    • 1
  • V. B. Kraus
    • 4
  • F. Qian
    • 5
  • Xiaoming Shi
    • 6
    • 10
    Email author
  • D. B. Matchar
    • 2
    • 7
  • Y. Zeng
    • 8
    • 9
  1. 1.Division of Non-Communicable Disease Control and Community HealthChinese Center for Disease Control and PreventionBeijingChina
  2. 2.Health Services and Systems ResearchDuke-NUS Graduate Medical School SingaporeSingaporeSingapore
  3. 3.Department of Sociology and Anthropology; Department of Human Development and Family StudiesUniversity of Rhode IslandKingstonUSA
  4. 4.Duke Molecular Physiology Institute, Department of MedicineDuke University School of MedicineDurhamUSA
  5. 5.Center for Clinical Cancer Genetics and Global Health, Department of MedicineUniversity of ChicagoChicagoUSA
  6. 6.Institute of Environmental Health and Related Product SafetyChinese Center for Disease Control and PreventionBeijingChina
  7. 7.Division of General Internal Medicine, Department of MedicineDuke University School of MedicineDurhamUSA
  8. 8.Center for the Study of Aging and Human Development and the Geriatric Division of School of MedicineDuke UniversityDurhamUSA
  9. 9.Center for Study of Healthy Aging and Development StudiesPeking UniversityBeijingChina
  10. 10.BeijingChina

Personalised recommendations